Advertisement

Central European Journal of Medicine

, Volume 4, Issue 2, pp 164–170 | Cite as

Benefit of antibiotic therapy on pouchitis after ileal pouch anal anastomosis: A systematic review and meta-analysis of clinical trials

  • Behzad Elahi
  • Shekoufeh Nikfar
  • Saeed Derakhshani
  • Mohammad Vafaie
  • Mohammad Abdollahi
Research Article
  • 41 Downloads

Abstract

The aim of the study was to evaluate and collect current evidence on the effect of antibiotics in pretreatment of pouchitis after restorative ileal pouch anal anastomosis (IPAA). Pubmed, Embase, Web of Science, Scopus, and Cochrane Library databases were searched between 1966 and July 2008; and relevant clinical trials extracted, reviewed, and validated according to the study protocol. The outcome of interest was clinical improvement after treatment. Nine randomized, placebo-controlled clinical trials were found relevant and studied but 3 of them with 70 patients were entered into meta-analysis. Pooling of the results from these trials yielded an odds ratio of 15.96 with a 95% CI of 4.20–60.70, indicating a significant OR (p<0.0001) in treatment group in comparison to the placebo group. In conclusion, the meta-analysis confirms benefit of antibiotics in management of pouchitis after IPAA operation.

Keywords

Meta-analysis Ileal pouch anal anastomosis Antibiotic Pouchitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Pricolo V.E., Ileal pouch-anal anastomosis: the ideal operation for ulcerative colitis and adenomatous polyposis coli? R. I. Med., 1994, 77, 382–384PubMedGoogle Scholar
  2. [2]
    Blumberg D., Beck D.E., Surgery for ulcerative colitis, Gastroenterol. Clin. North Am., 2002, 31, 219–235Google Scholar
  3. [3]
    Aziz O., Athanasiou T., Fazio V.W., Nicholls R.J., Darzi A.W., Church J., et al., Meta-analysis of observational studies of ileorectal versus ileal pouch-anal anastomosis for familial adenomatous polyposis, Br. J. Surg., 2006, 93, 407–417PubMedCrossRefGoogle Scholar
  4. [4]
    Keighley M.R., Review article: the management of pouchitis. Aliment. Pharmacol. Ther., 1996, 10, 449–457PubMedCrossRefGoogle Scholar
  5. [5]
    Nicholls R.J., Belliveau P., Neill M., Wilks M., Tabaqchali S., Restorative proctocolectomy with ileal reservoir: a pathophysiological assessment, Gut, 1981, 22, 462–468PubMedCrossRefGoogle Scholar
  6. [6]
    Zuccaro G.Jr., Fazio V.W., Church J.M., Lavery I.C., Ruderman W.B., Farmer R.G., Pouch ileitis, Dig. Dis. Sci., 1989, 34, 1505–1510PubMedCrossRefGoogle Scholar
  7. [7]
    Tytgat G.N., van Deventer S.J., Pouchitis, Int. J. Colorectal Dis., 1988, 3, 226–228PubMedCrossRefGoogle Scholar
  8. [8]
    Simchuk E.J., Thirlby R.C., Risk factors and true incidence of pouchitis in patients after ileal pouchanal anastomoses, World J. Surg., 2000, 24, 851–856PubMedCrossRefGoogle Scholar
  9. [9]
    Kmiot W.A., Youngs D., Tudor R., Thompson H., Keighley M.R., Mucosal morphology, cell proliferation and faecal bacteriology in acute pouchitis, Br. J. Surg. 1993, 80, 1445–1449PubMedCrossRefGoogle Scholar
  10. [10]
    Rahimi R., Nikfar S., Rezaie A., Abdollahi M., A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn’s disease, Clin. Ther., 2006, 28, 1983–1988PubMedCrossRefGoogle Scholar
  11. [11]
    Rahimi R., Nikfar S., Rezaie A., Abdollahi M., A metaanalysis of antibiotic therapy for active ulcerative colitis, Dig. Dis. Sci., 2007, 52, 2920–2925PubMedCrossRefGoogle Scholar
  12. [12]
    Baker D.E., Rifaximin: a nonabsorbed oral antibiotic, Rev. Gastroenterol. Disord., 2005, 5, 19–30PubMedGoogle Scholar
  13. [13]
    Ewaschuk J.B., Tejpar Q.Z., Soo I., Madsen K., Fedorak R.N., The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease, Curr. Gastroenterol. Rep., 2006, 8, 486–498PubMedCrossRefGoogle Scholar
  14. [14]
    Gionchetti P., Rizzello F., Lammers K.M., Morselli C., Sollazzi L., Davies S., et al., Antibiotics and probiotics in treatment of inflammatory bowel disease, World J. Gastroenterol., 2006, 12, 3306–3313PubMedGoogle Scholar
  15. [15]
    Gionchetti P., Rizzello F., Venturi A., Ugolini F., Rossi M., Brigidi P., et al., Antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach, Eur. Rev. Med. Pharmacol. Sci., 1999, 3, 27–30PubMedGoogle Scholar
  16. [16]
    Sachar D.B., How do you treat refractory pouchitis and when do you decide to remove the pouch? Inflamm. Bowel Dis., 1998, 4, 165–166PubMedCrossRefGoogle Scholar
  17. [17]
    Sandborn W.J., McLeod R., Jewell D.P., Medical therapy for induction and maintenance of remission in pouchitis: a systematic review, Inflamm. Bowel Dis. 1999, 5, 33–39PubMedGoogle Scholar
  18. [18]
    Madden M.V., McIntyre A.S., Nicholls R.J., Doubleblind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis, Dig. Dis. Sci., 1994, 39, 1193–1196PubMedCrossRefGoogle Scholar
  19. [19]
    Sambuelli A., Boerr L., Negreira S., Gil A., Camartino G., Huernos S., et al., Budesonide enema in pouchitis-a double-blind, double-dummy, controlled trial, Aliment. Pharmacol. Ther. 2002, 16, 27–34PubMedCrossRefGoogle Scholar
  20. [20]
    Shen B., Fazio V., Remzi F., Bennett A., Lopez R., Brzezinski A., et al., Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis, Dis. Col. Rectum., 2007, 50, 498–508CrossRefGoogle Scholar
  21. [21]
    Isaacs K.L., Sandler R.S., Abreu M., Picco M.F., Hanauer S.B., Bickston S.J., et al., Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study, Inflamm. Bowel Dis., 2007, 13, 1250–1255PubMedCrossRefGoogle Scholar
  22. [22]
    Shen B., Achkar J.P., Lashner B.A., Ormsby A.H., Remzi F.H., Brzezinski A., et al., A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis, Inflamm. Bowel Dis., 2001, 7, 301–305PubMedCrossRefGoogle Scholar
  23. [23]
    Nygaard K., Bergan T., Bjorneklett A., Hoverstad T., Lassen J., Aase S., Topical metronidazole treatment in pouchitis, Scand. J. Gastroenterol., 1994, 29, 462–467PubMedCrossRefGoogle Scholar
  24. [24]
    Egger M., Smith G.D., Phillips A.N., Meta-analysis: principles and procedures, B. M. J., 1997, 315, 1533–1537Google Scholar
  25. [25]
    Abdelrazeq A.S., Kelly S.M., Lund J.N., Leveson S.H., Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis, Colorectal Dis., 2005, 7, 182–186PubMedCrossRefGoogle Scholar
  26. [26]
    Abitbol V., Chaussade S., Pouchitis after ileal pouchanal anastomosis. Gastroenterol. Clin. Biol., 1997, 21, 299–304PubMedGoogle Scholar
  27. [27]
    Becker J.M., Stucchi A.F., Bryant D.E., How do you treat refractory pouchitis and when do you decide to remove the pouch? Inflamm. Bowel Dis., 1998, 4, 167–169PubMedCrossRefGoogle Scholar
  28. [28]
    Gerard L., Garey K.W., DuPont H.L., Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections, Expert. Rev. Anti. Infect. Ther., 2005, 3, 201–211PubMedCrossRefGoogle Scholar
  29. [29]
    Gionchetti P., Amadini C., Rizzello F., Venturi A., Poggioli G., Campieri M., Diagnosis and treatment of pouchitis, Best Pract. Res. Clin. Gastroenterol., 2003, 17, 75–87PubMedCrossRefGoogle Scholar
  30. [30]
    Mimura T., Rizzello F., Helwig U., Poggioli G., Schreiber S., Talbot I.C., et al., Four-week openlabel trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis, Aliment. Pharmacol. Ther., 2002, 16, 909–917PubMedCrossRefGoogle Scholar
  31. [31]
    Madiba T.E., Bartolo D.C., Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome. J. R. Coll. Surg. Edinb., 2001, 46, 334–337PubMedGoogle Scholar
  32. [32]
    Gionchetti P., Rizzello F., Venturi A., Ugolini F., Rossi M., Brigidi P., et al., Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis, Aliment. Pharmacol. Ther., 1999, 13, 713–718PubMedCrossRefGoogle Scholar
  33. [33]
    Shen B., Remzi F.H., Lopez A.R., Queener E., Rifaximin for maintenance therapy in antibioticdependent pouchitis, BMC Gastroenterol., 2008, 23, 26CrossRefGoogle Scholar
  34. [34]
    Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers K.M., Brigidi P., et al., Prophylaxis of pouchitis onset with probiotic therapy: a doubleblind, placebo-controlled trial, Gastroenterology, 2003, 124, 1202–1209PubMedCrossRefGoogle Scholar
  35. [35]
    Elahi B., Nikfar S., Derakhshani S., Vafaie M., Abdollahi M., Benefit of probiotics in the control of pouchitis in patients underwent ileal pouch anal anastomosis operation; A meta-analysis of controlled clinical trials, Dig. Dis. Sci., 2007, 53, 1278–1284PubMedCrossRefGoogle Scholar
  36. [36]
    Sambuelli A., Boerr L., Negreira S., Gil A., Camartino G., Huernos S., et al., Budesonide enema in pouchitis—a double-blind, double-dummy, controlled trial, Aliment. Pharmacol. Ther., 2002, 16, 27–34PubMedCrossRefGoogle Scholar
  37. [37]
    Gionchetti P., Rizzello F., Venturi A., Ferretti M., Brignola C., Peruzzo S., et al., Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis, Aliment. Pharmacol. Ther., 1997, 11, 673–678PubMedCrossRefGoogle Scholar
  38. [38]
    Wischmeyer P., Pemberton J.H., Phillips S.F., Chronic pouchitis after ileal pouch-anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study, Mayo Clin. Proc., 1993, 68, 978–981PubMedGoogle Scholar
  39. [39]
    Levin K.E., Pemberton J.H., Phillips S.F., Zinsmeister A.R., Pezim M.E., Role of oxygen free radicals in the etiology of pouchitis. Dis. Colon Rectum, 1992, 35, 452–456PubMedCrossRefGoogle Scholar
  40. [40]
    Hurst R.D., Molinari M., Chung T.P., Rubin M., Michelassi F., Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy, Arch. Surg., 1996, 131, 497–500PubMedGoogle Scholar
  41. [41]
    Rahimi R., Nikfar S., Rezaie A., Abdollahi M., A metaanalysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: evidence for prevention of disease relapse and maintenance of remission, Arch. Med. Sci. 2008, 4, 185–190Google Scholar
  42. [42]
    Rahimi R., Nikfar S., Rahimi F., Elahi B., Derakhshani S., Vafaie M., et al., A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn’s disease, Dig. Dis. Sci., 2008, 53, 2524–2531PubMedCrossRefGoogle Scholar
  43. [43]
    Nikfar S., Rahimi R., Rahimi F., Derakhshani S., Abdollahi M., Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials, Dis. Col. Rectum, 2008, 51, 1775–1780CrossRefGoogle Scholar
  44. [44]
    Fric P., Probiotics and prebiotics; resistance of a therapeutic principle, Cent. Eur. J. Med., 2007, 2, 237–270.CrossRefGoogle Scholar
  45. [45]
    Rahimi R., Nikfar S., Abdollahi M., Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: A meta-analysis of randomized controlled trials, Arch. Med. Sci., 2008, 4, 71–76Google Scholar
  46. [46]
    Talley N.J., Newer antidepressants in irritable bowel syndrome: what is the evidence? Arch. Med. Sci., 2008, 4, 77–78.Google Scholar
  47. [47]
    Rahimi R., Nikfar S., Abdollahi M., Meta-analysis technique confirms the effectiveness of anti-TNF-a in the management of active ulcerative colitis when administered in combination with corticosteroids, Med. Sci. Monit., 2007, 13, PI13–PI18PubMedGoogle Scholar
  48. [48]
    Rahimi, R., Nikfar, S., Abdollahi M., Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn’s disease? A systematic meta-analysis of controlled clinical trials, Biomed. Pharmacother., 2007, 61, 75–80PubMedCrossRefGoogle Scholar
  49. [49]
    Hosseini-Tabatabaei A., Abdollahi M., Potassium channel openers and improvement of toxic stress: do they have role in the management of inflammatory bowel disease? Inflamm. Allergy Drug Targets, 2008, 7, 129–135PubMedCrossRefGoogle Scholar
  50. [50]
    Rezaie A., Parker R.D., Abdollahi M., Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig. Dis. Sci., 2007, 52, 2015–2021PubMedCrossRefGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Behzad Elahi
    • 1
  • Shekoufeh Nikfar
    • 2
  • Saeed Derakhshani
    • 3
  • Mohammad Vafaie
    • 3
  • Mohammad Abdollahi
    • 4
  1. 1.Division of Neurology, Institute of Medical SciencesUniversity of TorontoTorontoCanada
  2. 2.Food and Drug Affairs, and Food & Drug Laboratory Research CenterMinistry of Health & Medical EducationTehranIran
  3. 3.Baharan Coloproctology Surgical ClinicTehranIran
  4. 4.Faculty of Pharmacy, and Pharmaceutical Sciences Research CenterTehran University of Medical SciencesTehranIran

Personalised recommendations